SEP 20, 2020 3:30 PM PDT

New Drug Shows Promise in Treating Advanced COVID-19

WRITTEN BY: Annie Lennon

As the COVID-19 pandemic rages on, the search for drugs to combat the virus is ongoing. Now, scientists have found that a new drug, known as 4-Phenulbutiric acid (4-PBA), can modulate the body's inflammatory response to COVID-19 in animals. 

In the study, the authors note that the inflammatory process common in patients with severe cases of COVID-19 causes the release of cytokines- immune cells that then put the body's immune system into overdrive in what's known as a cytokine storm. Leading blood vessels to become extremely permeable, it often results in multiple organ failure and then death. As such, treating these cytokine storms is essential for managing the disease. 

Already, 4-PBA, under the name 'Buphenyl', is used as an anti-stress drug against other diseases that modulate cellular stress, including urea cycle disorders. As such, the researchers set out to see whether the drug could also be used to combat similar stress caused by COVID-19. 

From animal tests, the researchers confirmed that the treatment was able to 'fully curb mortality caused by respoirtory failure from cellular stress'. 

The researchers also managed to identify the endoplasmic reticulum resistant protein, 'Binding Immunoglobulin Protein' (BiP), a biomarker for cellular stress in the blood. They managed to do so by finding a correlation between high levels of the biomarker and inflammatory severity from COVID-19 infections. 

As such, the researchers say that BiP levels could both serve as an early indicator for how effective 4-BPA treatment may be, as well as to indicate groups at more risk of severe complications from COVID-19. 

"Therefore, if we know that the patient suffers from cellular stress, we can kill two birds with one stone - we can detect susceptibility before infection occurs and know how to treat it in due time," says co-author of the study, Ivan Duran, from the University of Malaga in Spain. 

 

Sources: Deccan HeraldFDA

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
DEC 31, 2020
Immunology
Arthritis Medication Resolves Previously Untreatable Skin Condition
DEC 31, 2020
Arthritis Medication Resolves Previously Untreatable Skin Condition
Bumpy, inflamed, ring-shaped lesions on the skin—granuloma annulare (GA) is a chronic, inflammatory skin condition ...
JAN 11, 2021
Cell & Molecular Biology
Ginger May Help Slow Lupus or Antiphospholipid Syndrome Progression
JAN 11, 2021
Ginger May Help Slow Lupus or Antiphospholipid Syndrome Progression
Naturally occurring chemicals make more appealing medicines for many people, but there is not always evidence that they' ...
FEB 10, 2021
Drug Discovery & Development
Genetics Affect Response to Cancer Immunotherapy
FEB 10, 2021
Genetics Affect Response to Cancer Immunotherapy
Researchers have found that genetic factors may dictate as much as 20% of the efficacy of checkpoint inhibitors, a kind ...
MAR 09, 2021
Drug Discovery & Development
Leprosy Drug Repurposed for Potential COVID19 Treatment
MAR 09, 2021
Leprosy Drug Repurposed for Potential COVID19 Treatment
New research published in Nature study shows that a drug for treating leprosy was repurposed to treat COVID19. The study ...
APR 01, 2021
Microbiology
Mapping the Wild Microbiome to Search for Therapeutic Agents
APR 01, 2021
Mapping the Wild Microbiome to Search for Therapeutic Agents
Many people think of bacteria as disgusting germs, but there are plenty of important bacterial species that provide us w ...
APR 17, 2021
Drug Discovery & Development
Nanofiber-Based Drug Treats Inflammation
APR 17, 2021
Nanofiber-Based Drug Treats Inflammation
Researchers at Duke University worked on creating a self-assembling nanomaterial-based drug that can help address damage ...
Loading Comments...